Test Code HIVRFL HIV-1 p24 Antigen and Total Antibodies to HIV-1 and HIV-2 in Plasma (with Reflex)
Specimen and Container/Tube
Specimen Type: Plasma
Preferred Specimen: Lavendar Top
Specimen Handling and Transport Instructions
UCMC Onsite Instructions:
Collect specimen per standard collection procedure and send to laboratory immediately.
UCMC Offsite and UC MedLab Outreach Instructions:
- Samples should be centrifuged within 2 hours of collection.
- Centrifuge specimens at >2500 x g for 10 minutes at room temperature.
- Aliquot sample into plastic transport tube containing a minimum of 0.2 mL of specimen.
- Samples must be sent room temperature at 15-25oC.
Rejection Criteria
- Common specimen rejected situations include: incorrect specimen type, insufficient volume, missing or incomplete specimen identifiers, incorrect specimen transport, or specimens outside stability limits.
- Specimens that are clotted or grossly hemolyzed.
- Specimens that were transported unspun/whole blood and draw time is greater than 6 hours
Reference Values
This is a qualitative test.
Test |
Age |
Sex |
Reference Range (COI) |
Interpretation |
HIVDUO |
All |
All |
<1.0 |
Non-Reactive |
HIVDUO | All | All | ≥1.0 | Initially Reactive (Repeat to Confirm) |
HIVAg |
All |
All |
<1.0 |
Non-Reactive |
HIVAg | All | All | ≥1.0 | Reactive |
HIVAb |
All |
All |
<1.0 |
Non-Reactive |
HIVAb | All | All | ≥1.0 | Reactive |
Critical Values
Analyte |
Unit |
Low |
High |
Age |
N/A |
N/A |
N/A |
N/A |
N/A |
CPT Codes
87389
LOINC Codes
56888-1
Volume
Preferred Volume: 0.5 mL
Minimum Volume: 0.2 mL
Specimen Stability
Storage Temperature |
Stability |
Room Temperature |
7 days |
Refrigerated |
4 weeks |
Frozen |
3 months* |
* Please refer to Microbiology/Immunology procedures for stability claims for HIVSD and Mayo's website for Viral Load testing requirements. Plasma must be separated from the red cells within 24 hours of collection.
Note: May be frozen up to 6 times.
Collection Instructions
Collect specimen per standard laboratory collection procedures.
Test Components
HIVDUO
Clinical Indications
AIDS is caused by 2 known types of HIV. HIV type 1 (HIV-1) is found in patients with AIDS or AIDS-related complex, and in asymptomatic infected individuals at high risk for AIDS. The virus is transmitted by sexual contact, by exposure to infected blood or blood products, or from an infected mother to her fetus or infant. HIV type 2 (HIV-2) infection is endemic only in West Africa and it has been identified in individuals who had sexual relations with individuals from that geographic region. HIV-2 is similar to HIV-1 in viral morphology, overall genomic structure, and its ability to cause AIDS.
Antibodies against HIV-1 and HIV-2 are usually not detectable until 6 to 12 weeks following exposure and are almost always detectable by 12 months. They may fall to undetectable levels (ie, seroreversion) in the terminal stage of AIDS when the patient’s immune system is severely depressed, but HIV p24 antigen should be detectable and yield reactive results with the HIV antigen-antibody combination detection assays.
Methodology
Electrochemiluminescence immunoassay (ECLIA) (Roche Diagnostics)
Additional Information
Routine serologic screening of patients at risk for HIV-1 or HIV-2 infection usually begins with a HIV-1/-2 antigen and/or antibody screening test, which may be performed by various US Food and Drug Administration-approved assay methods, including rapid HIV antibody tests, enzyme immunoassays, and chemiluminescent immunoassays. In testing algorithms that begin with these methods, supplemental or confirmatory testing should be requested only for specimens that are repeatedly reactive by these methods.
Turnaround Time
Turnaround times are relative to the time the specimen is received in the test laboratory.
STAT Turnaround Time: 1 hour
Routine Turnaround Time: up to 4 hours
Testing Schedule: 24/7
Synonyms/Keyword Search
Acquired Immune Deficiency Syndrome (AIDS)
Anti-HIV
Anti-HIV-1/-2
HIV combo
HIV Types 1 and 2 Antibodies
HIV-1/-2
HIV-1/-2 Ab
HIV-1/-2 Ag/Ab
HIV-1/-2 Antibodies
HIV-1/-2 Antigen
Human Immunodeficiency Virus (HIV)
HIVDUO
Last Review Date
07/02/2024